Skip to contentB
BioCardia, Inc.
B
BCDABioCardia, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$46.00K$46.00Kderived−78.5% vs Q4 2019 Net Income-$2.99M-$2.99MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCardia, Inc. · CIK 925741 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,498,000N/M Operating Cash Flowderived-$3,417,000N/M Free Cash Flowderived-$3,417,000N/M Margins · derivedOperating margin-7604.3%−5951.5 pt vs Q4 2019
Net margin-6497.8%−4861.4 pt vs Q4 2019
ended Dec 31, 2020 · filed Mar 30, 2021 · 89 d after period end